Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019003164) USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING CANCERS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/003164 International Application No.: PCT/IB2018/054784
Publication Date: 03.01.2019 International Filing Date: 27.06.2018
IPC:
A61K 39/395 (2006.01) ,A61P 35/00 (2006.01) ,A61K 39/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
Applicants:
NEURACLE SCIENCE CO., LTD. [KR/KR]; 702-2, Sanhakwan, 145, Anam-ro Seongbuk-Gu Seoul 02841, KR
Inventors:
KIM, BongCheol; KR
CHO, Eun Bee; KR
KIM, Dong Sik; KR
LEE, Jae-Keun; KR
KWON, Soon-gu; KR
SEONG, Jae Young; KR
SHIM, Juwon; KR
KIM, Tae Woo; KR
KANG, Shin-hyuk; KR
Priority Data:
62/525,63327.06.2017US
62/582,88607.11.2017US
62/597,92012.12.2017US
Title (EN) USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING CANCERS
(FR) UTILISATION D'ANTICORPS ANTI-FAM19A5 POUR LE TRAITEMENT DE CANCERS
Abstract:
(EN) The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.
(FR) La présente invention concerne l'utilisation pharmaceutique d'antagonistes (par exemple, un anticorps ou une partie de liaison à un antigène de celui-ci) qui se lient spécifiquement à FAM19A5 pour favoriser la normalisation d'un vaisseau sanguin et traiter une maladie (par exemple, le cancer) chez un sujet qui en a besoin, par exemple, en favorisant la normalisation d'un vaisseau sanguin.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)